Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States DOI
John W. Ostrominski, Janinne Ortega-Montiel, Helen Tesfaye

et al.

Annals of Internal Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: April 14, 2025

Recent trends in use of tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide receptor agonist (RA), versus other glucose-lowering medications (GLMs) weight-lowering (WLMs) remain unexplored. To describe insurance claims for GLMs WLMs after tirzepatide approval. Population-based cohort study. Claims data from large U.S. commercial database (January 2021 to December 2023). Adults (aged ≥18 years) with type 2 diabetes (T2D) without dispensations WLMs. Any was defined as medication dispensation regardless prior use. Incident the preceding year. Monthly before market entry. Tirzepatide uptake additionally compared initial postapproval increased markedly among adults T2D prescribed GLMs, reaching 12.3% all GLM by 2023. Similar patterns were observed sodium-glucose cotransporter-2 inhibitors (14.5% 24.4%) GLP-1 RAs (19.5% 28.5%). Dispensations including metformin, declined. Among but WLMs, (0.0% 40.6%) semaglutide (2.4 mg) 32.2%) sharply, (2.0 most frequently dispensed WLM, increasing 37.8% 45.7%. incident users. more rapid sustained periods medications. Generalizability health is uncertain. These findings highlight sharp entry enhance understanding rapidly shifting landscape prescribing National Institute Diabetes Digestive Kidney Diseases.

Language: Английский

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists DOI Creative Commons
Apurva Khedagi,

Cara Hoke,

Michelle D. Kelsey

et al.

American Journal of Preventive Cardiology, Journal Year: 2023, Volume and Issue: 13, P. 100477 - 100477

Published: Feb. 24, 2023

Cardiovascular disease remains one of the most prominent global health problems and has been demonstrated to disproportionally affect certain communities. Despite an increasing collective effort improve inequalities, a multitude disparities continue cardiovascular outcomes. Among within prevention are with use distribution sodium-glucose cotransporter-2 (SGLT-2) inhibitors glucagon-like peptide 1 (GLP-1) receptor agonists. Several landmark trials have efficacy these novel agents, not only in among those diabetes, but also heart failure chronic kidney disease. However, agents limited by racial/ethnic, sex, socioeconomic groups. This review works highlight understand differences on prescribing patterns pivotal prevention, SGLT-2 GLP-1 Our aim is enrich understanding inspire efforts end morbidity mortality due race, sex income inequality.

Language: Английский

Citations

13
Projected impact of anti‐obesity pharmacotherapy use on racial and ethnic disparities in adolescent obesity DOI
Mary Ellen Vajravelu, Patricia Y. Chu, David A. Frank

et al.

Pediatric Obesity, Journal Year: 2024, Volume and Issue: 19(4)

Published: Feb. 6, 2024

Paediatric obesity disproportionately impacts individuals from minoritized racial and ethnic backgrounds. Recent guidelines support use of anti-obesity pharmacotherapy for adolescents with obesity, but the potential impact on disparities in prevalence has not been evaluated.

Language: Английский

Citations

5
Breaking Barriers: Tackling Racial and Socioeconomic Disparities in the Prescription of Life-Saving SGLT2 Inhibitors for Proteinuria DOI Open Access

Shay Taylor,

Samrawit W Zinabu,

E McMillan

et al.

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 8, 2025

The underutilization of sodium-glucose co-transporter type 2 inhibitors (SGLT2i), despite their proven cardiovascular and renal benefits, raises concerns about healthcare equity. SGLT2i effectively reduces proteinuria, a key indicator kidney disease, making them an essential treatment for individuals with or without diabetes, particularly those at higher risk, such as the Black American population, who have prevalence proteinuria. However, studies show disparities in prescriptions race, ethnicity, socioeconomic status contributing to lower utilization rates among vulnerable populations. This study aims explore prescription patterns Maryland, focusing on patients proteinuria address these improve access care. objective was identify racial SGLT2i. retrospective cohort utilized de-identified electronic health records (EHR) sourced from Epic database across University Maryland Medical System (UMMS), spanning 10-year period January 1, 2014, December 31, 2023, evaluated Of 5,866,616 UMMS system, 28,136 were diagnosed whom 4,360 (15.5%) prescribed medications. Among receiving prescriptions, 37.9% self-identified American, while 54.7% identified White American. Notable geographical observed rates. In affluent areas Fulton, MD (zip code 20759), only 0.046% received compared 1.4% lower-income area West Baltimore, 21223). Bivariate analysis revealed significant rates, having odds (OR = 0.68, p < 0.001) like Fulton showing significantly Baltimore 0.31, 0.001). These persisted multivariate analysis, where had adjusted PR (AOR) 0.72 (p 0.002) relative patients, residents (AOR 1.72, 0.01) reduced 0.35, 0.02). reveals United States, highlighting influence factors vital treatments. Despite established benefits managing reducing risk systemic inequities persist, potentially leaving high-risk populations underserved. findings call deeper examination structural barriers disparities, well development strategies promote equitable Ensuring that all regardless background status, evidence-based therapies is improving outcomes inequities.

Language: Английский

Citations

0
Large Language Models in Diabetes Management: The Need for Human and Artificial Intelligence Collaboration DOI
Juliessa M. Pavon,

David Schlientz,

Matthew L. Maciejewski

et al.

Diabetes Care, Journal Year: 2025, Volume and Issue: 48(2), P. 182 - 184

Published: Jan. 22, 2025

Language: Английский

Citations

0
Use of Antihyperglycemic Medications Among US People with Limited English Proficiency DOI Creative Commons
Frank Müller, Harland Holman,

Nikita Bhangu

et al.

Journal of General Internal Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 28, 2025

Abstract Background Language barriers can impact pharmaceutical disease management leading to potential health disparities among limited English proficiency (LEP) people with diabetes mellitus (DM) in the United States (US). Objective To assess use of antihyperglycemic medications and estimate their on glycemic control by LEP status. Design Cross-sectional design. We compared classes prescribed between English-speaking participants (i.e., Spanish-speaking or needing interpretation services) DM applying generalized linear models adjusting for sociodemographic variables. Participants Data from US National Health Nutrition Examination Survey (NHANES 2003–2018). Main Measures Selected language interview interpreter request (main exposure). Outcomes include (HBA1c). Key Results 4666 were analyzed. Antihyperglycemic similarly used DM, except insulin, which was less frequently people. Despite similar medications, using biguanides TZDs likely reach target levels (adjusted odds ratios ranging 1.7 3.3) DM. Conclusions Our findings indicate that differences outcomes are attributed factors other than medication prescription. These might cultural beliefs, dietary adjustments, communication healthcare. Enhanced patient education, acknowledgment practices, improved services could potentially mitigate these disparities.

Language: Английский

Citations

0
Patient and physician factors driving the gaps in use of drugs with cardiovascular and kidney benefits by medicare beneficiaries with type 2 diabetes treated by endocrinologists, nephrologists, and cardiologists: Population-based cohort study DOI Creative Commons
Rozalina G. McCoy, Jonathan L. Vandergrift, Bradley M. Gray

et al.

Diabetes Research and Clinical Practice, Journal Year: 2025, Volume and Issue: 221, P. 112039 - 112039

Published: Feb. 7, 2025

Endocrinologists, nephrologists, and cardiologists care for people with type 2 diabetes (T2D) coexisting cardiovascular disease (CVD), heart failure (HF), and/or chronic kidney (CKD). Glucagon-like peptide-1 receptor agonists (GLP-1RA) sodium-glucose cotransporter inhibitors (SGLT2i) should be preferentially used, but are underutilized. We examine patient physician factors associated GLP-1RA/SGLT2i use by patients treated these subspecialists. Retrospective cohort study using linked 2022 Medicare American Board of Internal Medicine data adults >65 years T2D CVD, HF, CKD their treating endocrinologists, cardiologists. identified 246,106/254,425/435,773 5,661/8,233/10,874 endocrinologists/nephrologists/cardiologists in 2022. Overall, 73.2 % endocrinologist-treated filled medications prescribed endocrinologists; 41.9 GLP-1RA/SGLT2i. Patients nephrologists were rarely subspecialists (9.8 6.1 %, respectively); however, conditional on filling any medication, they more likely to fill a (59.5 48.2 respectively). Older endocrinologists older cardiologists, less Many, particularly older, be, not, GLP-1RA/SGTL2i. Physician training may improve statistics.

Language: Английский

Citations

0
Race and ethnic disparities in insulin pump and continuous glucose monitor use between 2017 and 2024: a systematic review with a focus on health equity DOI Creative Commons
Patricia Underwood,

Kathryn Chirokas,

Jordan N. Keels

et al.

Deleted Journal, Journal Year: 2025, Volume and Issue: 2(1)

Published: Feb. 13, 2025

Language: Английский

Citations

0
Racial and regional differences in efficacy of sodium-glucose cotransporter 2 inhibitors on cardiorenal outcomes: A systematic review and meta-analysis DOI
Ryoma Kani, Yoshihisa Miyamoto, Tetsuya Saito

et al.

International Journal of Cardiology, Journal Year: 2025, Volume and Issue: unknown, P. 133079 - 133079

Published: Feb. 1, 2025

Language: Английский

Citations

0
Another Win for SGLT2 Inhibitors in Chronic Kidney Disease DOI
David E. Leaf,

Nisha Bansal

New England Journal of Medicine, Journal Year: 2025, Volume and Issue: 392(8), P. 822 - 823

Published: Feb. 19, 2025

Chronic kidney disease affects 14% of the U.S. population1 and is associated with an extraordinarily high risk poor outcomes, including progression to end-stage disease, cardiovascular events, death.2 Finally, after decades therapeutic stagnation, a recent explosion new therapies has revolutionized treatment options in this vulnerable patient population. Prominent among these are sodium–glucose cotransporter 2 (SGLT2) inhibitors, as described landmark trials, EMPA-KIDNEY trial empagliflozin 2023.3 In issue Journal,4 Herrington et al. report long-term results follow-up involving patients chronic who .

Language: Английский

Citations

0
Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients With Type 2 Diabetes at Cardiology, Endocrinology, and Primary Care Visits DOI
Dave L. Dixon, Teresa M. Salgado,

Amanda Robinson

et al.

Mayo Clinic Proceedings, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

0